These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6279982)

  • 1. [A comparative study of cephotaxime and other antimicrobial agents in relationship to Pseudomonas aeruginosa (author's transl)].
    García Martos P; Rodríguez Sarmiento MT; García Herruzo J; Fernández Gutiérrez del Alamo C; Romera Cano MA; Martínez País Romaní R
    Med Clin (Barc); 1982 Feb; 78(4):148-51. PubMed ID: 6279982
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotic synergy: clinical applications and an in vitro study of cefotaxime-aminoglycoside combinations.
    Faris HM; Dreskin RB
    J S C Med Assoc; 1983 May; 79(5):275-7. PubMed ID: 6308348
    [No Abstract]   [Full Text] [Related]  

  • 3. [Possible use of pyocins against Pseudomonas aeruginosa (author's transl)].
    Sezen IY; Blobel H; Scharmann W
    Zentralbl Bakteriol Orig A; 1974; 229(2):205-8. PubMed ID: 4155865
    [No Abstract]   [Full Text] [Related]  

  • 4. [The "in vitro" sensitivity of pseudomonas aeruginosa to antibiotic and chemotherapeutic agents (author's transl)].
    Paredes L; Valenzuela E; Caorsi B; Castillo M
    Rev Med Chil; 1976 Sep; 104(9):615-9. PubMed ID: 828758
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pseudomonas aeruginosa infections].
    Tanaka E
    Naika; 1972; 29(2):286-90. PubMed ID: 4622605
    [No Abstract]   [Full Text] [Related]  

  • 6. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
    Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
    Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sensitivity in vitro to antibiotics and chemotherapeutic agents in various hospital strains of Pseudomonas aeruginosa].
    Bertaggia A; De Negri M
    Boll Ist Sieroter Milan; 1974; 50(1):45-53. PubMed ID: 4204863
    [No Abstract]   [Full Text] [Related]  

  • 8. [The "in vitro" susceptibility of pseudomonas aeruginosa to tobramycin (author's transl)].
    Fernández H; Otth L
    Rev Med Chil; 1976 Jul; 104(7):473-4. PubMed ID: 828757
    [No Abstract]   [Full Text] [Related]  

  • 9. Colistin: an antimicrobial for the 21st century?
    Stein A; Raoult D
    Clin Infect Dis; 2002 Oct; 35(7):901-2. PubMed ID: 12228836
    [No Abstract]   [Full Text] [Related]  

  • 10. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
    Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
    Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug selection for antimicrobial susceptibility testing (author's transl)].
    Kobayashi A
    Rinsho Byori; 1979 May; 27(5):385-92. PubMed ID: 114698
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.
    Scheetz MH; Esterly JS; Malczynski M; Postelnick M; Qi C
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):465-7. PubMed ID: 19394788
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro.
    Kobayashi Y; Sumitani Y; Sugita K; Aikawa N
    Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870
    [No Abstract]   [Full Text] [Related]  

  • 14. Surveillance of antimicrobial susceptibility of Pseudomonas aeruginosa clinical isolates from a central hospital in Portugal.
    Cardoso O; Alves AF; Leitão R
    J Antimicrob Chemother; 2007 Aug; 60(2):452-4. PubMed ID: 17576698
    [No Abstract]   [Full Text] [Related]  

  • 15. [Does a rational therapeutic plan exist for nosocomial bacteremia caused by Pseudomonas aeruginosa?].
    Torné J; García Flores A; Tomás S; Serrano R
    Med Clin (Barc); 1987 Oct; 89(13):572. PubMed ID: 3121961
    [No Abstract]   [Full Text] [Related]  

  • 16. Report: prevalence and resistance pattern of Pseudomonas aeruginosa against various antibiotics.
    Khan JA; Iqbal Z; Rahman SU; Farzana K; Khan A
    Pak J Pharm Sci; 2008 Jul; 21(3):311-5. PubMed ID: 18614431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metallo-beta-lactamases producing Pseudomonas aeruginosa in Algeria].
    Aggoune-Khinache N; Bensersa D; Henniche FZ; Daoudi M; Abdouni MA; Chabani A; Tiouit D; Naim M
    Med Mal Infect; 2009 Jun; 39(6):413-4. PubMed ID: 19111417
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative susceptibilities of 40 strains of Pseudomonas aeruginosa to 10 antipseudomonal antimicrobial agents.
    Davidson S; Lipshitz M; Bogokowski B; Rubinstein E
    Isr J Med Sci; 1982 Aug; 18(8):859-62. PubMed ID: 6811501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism of ceftizoxime and tobramycin for Pseudomonas aeruginosa.
    Kim C; Schick DG; Ashley MA; Montgomerie JZ
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():57-62. PubMed ID: 6296030
    [No Abstract]   [Full Text] [Related]  

  • 20. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.